117 related articles for article (PubMed ID: 31858407)
1. Tardive Reactivation of Progressive Multiple Sclerosis During Treatment with Biotin.
Demas A; Cochin JP; Hardy C; Vaschalde Y; Bourre B; Labauge P
Neurol Ther; 2020 Jun; 9(1):181-185. PubMed ID: 31858407
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
3. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
4. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
5. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
[TBL] [Abstract][Full Text] [Related]
6. High dose biotin as treatment for progressive multiple sclerosis.
Birnbaum G; Stulc J
Mult Scler Relat Disord; 2017 Nov; 18():141-143. PubMed ID: 29141796
[TBL] [Abstract][Full Text] [Related]
7. A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis.
Lebrun C; Cohen M; Mondot L; Ayrignac X; Labauge P
Neurol Ther; 2017 Dec; 6(2):259-263. PubMed ID: 28840523
[TBL] [Abstract][Full Text] [Related]
8. A new era in the treatment of multiple sclerosis.
Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies JM; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E
Med J Aust; 2015 Aug; 203(3):139-41, 141e.1. PubMed ID: 26224184
[TBL] [Abstract][Full Text] [Related]
9. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis.
Sedel F; Bernard D; Mock DM; Tourbah A
Neuropharmacology; 2016 Nov; 110(Pt B):644-653. PubMed ID: 26327679
[TBL] [Abstract][Full Text] [Related]
10. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
12. High doses of biotin in chronic progressive multiple sclerosis: a pilot study.
Sedel F; Papeix C; Bellanger A; Touitou V; Lebrun-Frenay C; Galanaud D; Gout O; Lyon-Caen O; Tourbah A
Mult Scler Relat Disord; 2015 Mar; 4(2):159-69. PubMed ID: 25787192
[TBL] [Abstract][Full Text] [Related]
13. Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients.
Ferraro D; Guicciardi C; De Biasi S; Pinti M; Bedin R; Camera V; Vitetta F; Nasi M; Meletti S; Sola P
Acta Neurol Scand; 2020 Jan; 141(1):16-21. PubMed ID: 31350854
[TBL] [Abstract][Full Text] [Related]
14. T2 lesions and rate of progression of disability in multiple sclerosis.
Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
[TBL] [Abstract][Full Text] [Related]
15. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
[TBL] [Abstract][Full Text] [Related]
16. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
17. Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis.
Dastidar P; Heinonen T; Lehtimäki T; Ukkonen M; Peltola J; Erilä T; Laasonen E; Elovaara I
J Neurol Sci; 1999 May; 165(1):36-42. PubMed ID: 10426145
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.
Peyro Saint Paul L; Debruyne D; Bernard D; Mock DM; Defer GL
Expert Opin Drug Metab Toxicol; 2016; 12(3):327-44. PubMed ID: 26699811
[TBL] [Abstract][Full Text] [Related]
19. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.
Rejdak K; Eikelenboom MJ; Petzold A; Thompson EJ; Stelmasiak Z; Lazeron RH; Barkhof F; Polman CH; Uitdehaag BM; Giovannoni G
Neurology; 2004 Oct; 63(8):1439-45. PubMed ID: 15505162
[TBL] [Abstract][Full Text] [Related]
20. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
